Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: MMP trumps all else

Exactly - no one bought because of RG or Crossflo.

While the MMP has proven to be a revenue source of nearly $300mio so far and has a billion market in near sight, Crossflo/PDSG has to show, IF it can succeed and when/if the market will be big enough for substantial revenues.

My guess is: We will see some more licensees in the next weeks, but it might last until end of October/start of November, until we hear something from a new CEO. The reason:

He needs to have enough time to get into the details of PTSC/PDSG in order to be able to manage the SHM in January (provided it isn't postponed).

IMHO - GLTY

Share
New Message
Please login to post a reply